A certificate of analysis, often shortened to COA, records results for a particular material and set of tests. It can be useful information. It does not, by itself, prove that a compounded sermorelin prescription is FDA-approved, clinically effective, or suitable for you.

The first question is what was tested: the raw ingredient, an intermediate preparation, or the finished medicine. This guide explains how to discuss the document with a pharmacist without treating a laboratory logo or a purity percentage as a complete quality assessment.

The considered take

Match the report to the material and lot, then ask what the tests cover. A raw-ingredient certificate is not a finished-vial safety guarantee.

Identify the material before reading the percentage

A supplier may provide a certificate for the active pharmaceutical ingredient used in compounding. That is a different item from a vial that has been prepared, filled, stored, and shipped for a patient. FDA advises compounders to understand their ingredient suppliers and the quality testing behind their materials.

Ask the pharmacy which stage the report describes and how that material connects to your prescription. If the document is for an ingredient, request an explanation of the controls for the finished preparation. The compounding-pharmacy checklist places this question alongside pharmacy identity and licensing.

Sources: FDA: Know your bulks and excipients suppliers · FDA: Compounding questions and answers

Look for an identifiable lot and meaningful results

FDA's Q7A guidance for active pharmaceutical ingredients describes certificate information such as the material identity, batch number, tests, acceptance limits, results, and authorized approval. It is ingredient-manufacturing guidance, not a promise that every patient has access to every pharmacy record.

Use those fields to ask focused questions. Does the report identify the material and date? Can the pharmacy explain how its lot records connect the report to your medicine? Are actual results and limits shown, or only a general statement that testing passed? A cropped screenshot without identifying details leaves those questions unanswered.

Sources: FDA: Q7A good manufacturing practice guidance for active pharmaceutical ingredients

Separate strength, sterility, and other quality questions

Different tests answer different questions. A strength result concerns the amount of drug measured. Sterility testing addresses microbial growth under the test conditions; endotoxin testing addresses a different contamination concern. FDA's quality-testing program lists distinct assays rather than one universal quality score.

A purity percentage should not be read as a substitute for all of these checks. Ask the pharmacist which tests and preparation controls are relevant to the actual dosage form. We have not tested any provider's vial or established that a particular public certificate represents everything dispensed through that service.

Sources: FDA: Drug quality sampling and testing programs · FDA: Risks of compounded drugs

Do not use a certificate to turn research powder into medicine

A research supplier may display laboratory results while labeling a product for laboratory use. The report does not establish a valid patient prescription, appropriate clinical supervision, or a preparation intended for human injection. Nor does a facility registration mean FDA approved a finished compounded drug.

If the seller cannot identify the licensed prescriber and dispensing pharmacy, a certificate does not resolve that gap. Start with how prescriptions are obtained, and ask a pharmacist about the source before considering the product. Avoid trying to solve a questionable supply chain by preparing a research material at home.

Sources: FDA: Compounding questions and answers · FDA: Know your bulks and excipients suppliers

Keep testing claims separate from treatment results

Even a relevant quality report cannot show that a medicine will improve sleep, memory, recovery, or weight for a particular person. Those are clinical questions requiring evidence about the drug, formulation, population, and outcome. A laboratory assay and a treatment trial have different purposes.

Our clinical-studies guide explains how to examine that second question. The Get Thin MD review shows how we handle provider testing claims: we describe what the site says while keeping independent batch verification and clinical benefit separate.

Sources: FDA: Managing the benefits and risks of medicines · Get Thin MD: Sermorelin injection program

Bring a short, specific request to the pharmacy

A useful message identifies your prescription and asks: what material does this report cover, how does it connect to my lot, what testing was completed, and who can explain the result? Share prescription details through the pharmacy's secure channel rather than posting an unredacted label publicly.

If a report or label suggests an actual quality problem, contact the dispensing pharmacy and prescriber for instructions. The recall and reporting guide explains the next steps. Keep the original packaging and document while the concern is assessed; a marketing representative's reassurance is not a substitute for a product-specific answer.

Sources: FDA: Consumer complaint system and MedWatch · FDA: Understanding drug recalls

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. FDA: Know your bulks and excipients suppliersRegulator guidance · Ingredient supply-chain guidance; an API certificate does not establish finished-vial quality.
  2. FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.
  3. FDA: Q7A good manufacturing practice guidance for active pharmaceutical ingredientsRegulator guidance · Section 11.4 describes API certificates of analysis. Not a universal patient disclosure rule for compounded finished products.
  4. FDA: Drug quality sampling and testing programsRegulator guidance · Illustrates distinct quality tests; does not establish testing of any sermorelin product reviewed here.
  5. FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
  6. FDA: Managing the benefits and risks of medicinesUS regulator · General questions for evaluating benefit, follow-up and new medicines.
  7. Get Thin MD: Sermorelin injection programProvider primary source · Checked visible offer and plan controls September 21, 2026; promotions and final checkout can differ.
  8. FDA: Consumer complaint system and MedWatchRegulator guidance · Patient reporting of medication quality problems and adverse events; not an emergency care channel.
  9. FDA: Understanding drug recallsRegulator guidance · Lot matching, risk classifications, and following the actual notice; not a claim about current sermorelin recall status.